Matinas Biopharma Holdings, Inc. stock is down -7.61% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 December’s closed higher than November.
Matinas BioPharma Holdings, Inc. focuses on the discovery and development of various product candidates. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients.